These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 1972054)

  • 21. Clinical profile of remoxipride--a combined analysis of a comparative double-blind multicentre trial programme.
    Lewander T; Westerbergh SE; Morrison D
    Acta Psychiatr Scand Suppl; 1990; 358():92-8. PubMed ID: 1978500
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A double-blind comparative study of remoxipride and haloperidol in acute schizophrenia.
    den Boer JA; Ravelli DP; Huisman J; Ohrvik J; Verhoeven WM; Westenberg HG
    Acta Psychiatr Scand Suppl; 1990; 358():108-10. PubMed ID: 1978468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selective dopamine D2 antagonist and prolactin response in acute schizophrenia--results from remoxipride studies. The Canadian Remoxipride Study Group.
    Awad AG; Lapierre YD; Jostell KG
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(5):769-77. PubMed ID: 2149882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A new substituted benzamide with neuroleptic effects: lin 14 18 or sultopride].
    Dufour H; Castelli J; Luccioni H; Scotto JC; Sutter JM
    Encephale; 1975; 1(1):15-8. PubMed ID: 1093843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity.
    Perrault G; Depoortere R; Morel E; Sanger DJ; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):73-82. PubMed ID: 8996184
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
    Lindström LH; Wieselgren IM; Struwe G; Kristjansson E; Akselson S; Arthur H; Andersen T; Lindgren S; Norman O; Naimell L
    Acta Psychiatr Scand Suppl; 1990; 358():130-5. PubMed ID: 1978472
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remoxipride and haloperidol in schizophrenia: a double-blind multicentre study.
    Ahlfors UG; Rimön R; Appelberg B; Hagert U; Harma P; Katila H; Mahlanen A; Mehtonen OP; Naukkarinen H; Outakoski J
    Acta Psychiatr Scand Suppl; 1990; 358():99-103. PubMed ID: 1978501
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double blind comparative multicentre study of remoxipride and haloperidol in schizophrenia.
    Andersen J; Kørner A; Ostergaard P; Fensbo C; Birket-Smith M; Thiesen S; Hansen NR; Fogh M; Kristensen M; Møller-Nielsen EM
    Acta Psychiatr Scand Suppl; 1990; 358():104-7. PubMed ID: 1978467
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Remoxipride, a selective dopamine D2 receptor antagonist, in tardive dyskinesia.
    Andersson U; Häggström JE; Nilsson MI; Widerlöv E
    Psychopharmacology (Berl); 1988; 94(2):167-71. PubMed ID: 2895483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A controlled dose-ranging study of remoxipride and haloperidol in schizophrenia--a Canadian multicentre trial.
    Lapierre YD; Nair NP; Chouinard G; Awad AG; Saxena B; Jones B; McClure DJ; Bakish D; Max P; Manchanda R
    Acta Psychiatr Scand Suppl; 1990; 358():72-7. PubMed ID: 1978496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New chemotherapy approaches to psychoses].
    Olié JP; Baylé FJ
    Encephale; 1997 Apr; 23 Spec No 2():2-9. PubMed ID: 9273302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
    Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
    J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation in both short- and long-term treatment of schizophrenia with remoxipride.
    Morrison D; Englund A; Lawrie V; Lewander T; Schlachet A; Westerbergh SE
    Acta Psychiatr Scand Suppl; 1990; 358():164-9. PubMed ID: 1978478
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A placebo controlled trial of remoxipride in the prevention of relapse in chronic schizophrenia.
    King DJ; Blomqvist M; Cooper SJ; Doherty MM; Mitchell MJ; Montgomery RC
    Psychopharmacology (Berl); 1992; 107(2-3):175-9. PubMed ID: 1352050
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma concentrations of remoxipride and haloperidol in relation to prolactin and short-term therapeutic outcome in schizophrenic patients.
    Lahdelma RL; Appelberg B; Kuoppasalmi K; Katila H; Rimón R
    Eur Neuropsychopharmacol; 1991 Dec; 1(4):535-40. PubMed ID: 1688013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone.
    Cohen LJ
    Pharmacotherapy; 1994; 14(3):253-65. PubMed ID: 7524043
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind comparative study of remoxipride and haloperidol in schizophrenic and schizophreniform disorders.
    Mendlewicz J; de Bleeker E; Cosyns P; Deleu G; Lotstra F; Masson A; Mertens C; Parent M; Peuskens J; Suy E
    Acta Psychiatr Scand Suppl; 1990; 358():138-41. PubMed ID: 1978474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Remoxipride, a new selective D2 antagonist, and haloperidol in cebus monkeys.
    Gerlach J; Casey DE
    Prog Neuropsychopharmacol Biol Psychiatry; 1990; 14(1):103-12. PubMed ID: 1967845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol.
    Classen W; Laux G
    Neuropsychobiology; 1989; 21(3):131-40. PubMed ID: 2575719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacology of the atypical antipsychotic remoxipride, a dopamine D2 receptor antagonist.
    Nadal R
    CNS Drug Rev; 2001; 7(3):265-82. PubMed ID: 11607043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.